INTEGRATE 2.0

Trial Name

Trial Number

Share this trial

What

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Why / Objectives

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

How

Toggle Content

Who / Patients

Toggle Content

Who / Partners

Toggle Content

When

Toggle Content

Where

Toggle Content

Related Publications

Toggle Content

Funding

Toggle Content

ClinicalTrials.gov

Toggle Content

More to explore

PANACEA

Panacea BIG 4-13 PANACEA stands for anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer. A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab

ALTTO

ALTTO BIG 2-06 Share This Post A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with

Breast International Group (BIG) – aisbl

Head Office

Tax Deduction

Donations greater than or equal to € 40 / year receive a 45% tax reduction. This means your donation of €40 only costs you € 22.

Site Links

The Breast International Group is proud to adhereto the Code of Ethics of the VEF-AERF

Co-funded by the European Union under an operating grant from the European Union’s EU4Health programme under grant agreement No 101124555. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

EN FR NL

Trial Number

Share this trial

More to explore

PANACEA

ALTTO

Head Office

Tax Deduction

Site Links

Ⓒ 2023- All Rights Are Reserved